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BACKGROUND. The immune-mediated graft-versus-tumor (GVT) effect plays a ther-
apeutic role in the treatment of patients with hematologic malignancies who
undergo allogeneic hematopoietic stem cell transplantation (HSCT). More re-
cently, it was reported that a GVT effect also occurred in patients who underwent
transplantation for metastatic renal carcinoma. The authors carried out a pilot trial
of allogeneic transplantation after a reduced-intensity, preparative regimen in
patients with refractory malignancies, including solid tumors. The objectives of the
current study were to evaluate the feasibility of this approach in terms of toxicity
and engraftment and to document evidence of GVT effects.
METHODS. Seventeen patients with Stage IV malignancies (7 patients with renal cell
carcinoma, 3 patients with sarcoma, 2 patients with breast carcinoma, 2 patients
with Hodgkin disease, 1 patient with ovarian carcinoma, 1 patient with melanoma,
and 1 patient with both melanoma and renal cell carcinoma) that were not
amenable to further conventional treatment were enrolled. The median patient age
was 43 years (range, 10 – 60 years). The Eastern Cooperative Oncology Group
performance status (PS) was 0 –1 in 11 patients and 2–3 in 6 patients. Preparative
treatment consisted of reduced-intensity chemotherapy with fludarabine (30
mg/m2 per day for 4 consecutive days) and cyclophosphamide (30 mg/Kg per day
for 2 consecutive days) prior to allogeneic HSCT from a human leukocyte antigen-
identical sibling. The median number of CD34 cells infused was 6.06 106/kg (range,
1.5–14.0  106/kg). Graft-versus-host disease (GVHD) prophylaxis consisted of cyclo-
sporin-A and short-term methotrexate.
RESULTS. Patients who had a PS of 2–3 prior to undergoing HSCT experienced
Grade 4 hematologic toxicities and Grade  3 organ toxicities and died of either
treatment-related complications or disease progression within 100 days from
transplantation. By contrast, 10 of 11 patients who had a PS of 0 –1 prior to
undergoing HSCT experienced only short-lasting, Grade  3 neutropenia and
thrombocytopenia and no organ toxicity; 1 of 10 patients died of graft failure on
Day 29 after undergoing HSCT. By Day 90, 100% donor chimerism was docu-
mented in all patients with a past history of heavy chemotherapy, whereas mixed
donor chimerism was observed in the 4 patients with a past history of only 1 line
of chemotherapy and/or immunotherapy prior to entering the HSCT program.
Grade 2–3 acute GVHD occurred in 5 patients. Among patients with a follow-up
 100 days, 2 complete responses and 3 transitory partial responses were recorded.
CONCLUSIONS. With this conditioning regimen, full donor chimerism was achieved
rapidly only in patients who had received previous intensive chemotherapy. In a
proportion of patients with refractory malignancies, allogeneic transplantation
resulted in tumor regression. This novel therapeutic strategy may provide little
benefit in patients with poor PS and rapidly progressing disease. Cancer 2002;94:
2409 –15. © 2002 American Cancer Society.
DOI 10.1002/cncr.10491
KEYWORDS: allogeneic blood stem cell transplantation, graft-versus-tumor disease,
performance status, refractory malignancies.
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Extensive clinical and experimental data support afavorable role for graft-versus-tumor (GVT) effects
in promoting a cure for patients with hematologic
malignancies who receive myeloablative therapy and
undergo allogeneic hematopoietic stem cell trans-
plantation (HSCT).1–3 Recent reports suggest that do-
nor lymphocytes transferred with the graft also may
produce a clinically meaningful GVT effect in patients
with refractory solid tumors.4 – 6 However, because of
the associated morbidity and mortality, myeloablative
high-dose chemotherapy (HDC) and allogeneic trans-
plantation are restricted to young, medically fit pa-
tients, thus excluding the vast majority of patients
from this therapy. Studies in animal models and in
humans have shown that sustained engraftment of
donor hematopoietic stem cells can be accomplished
with the use of preparative regimens that cause im-
munosuppression without ablating host hematopoie-
sis.7–10 When this approach is used for patients with
malignant disease, the clinical working hypothesis is
to attack the tumor through the donor’s immune sys-
tem rather than trying to wipe out tumor cells through
high-dose cytotoxic therapy.11 Nonmyeloablative
HSCT offers the advantage of low transplantation-
related mortality and provides for the development of
full donor lymphoid chimerism,12,13 and it has been
used successfully to treat patients with hematopoietic
malignancies and patients with certain genetic dis-
eases.9,13 In view of experimental evidence demon-
strating a GVT effect of allogeneic lymphocytes in
animals who were pretreated with a nonmyeloabla-
tive, preparative regimen,14,15 it is evident that this
approach also may be considered for the immuno-
therapy of solid tumors. Childs et al. recently reported
on the efficacy of a nonmyeloablative protocol fol-
lowed by HSCT from human leukocyte antigen (HLA)-
matched relatives in patients with metastatic renal
carcinoma (RCC).16 Ten of 19 patients who were en-
rolled in the latter study had measurable responses,
and 3 patients enjoyed complete, long-lasting re-
sponses. Although those results were promising, the
procedure was associated with severe graft-versus-
host disease (GVHD) and rapidly progressive disease
in a fraction of patients, and further refinement to
minimize complications and improve efficacy are re-
quired. Furthermore, patients with other solid tumors
that are resistant to conventional chemotherapy and
radiotherapy also may be suitable for this approach.
We report the results of a pilot study carried out in
17 patients with advanced and refractory malignan-
cies who were treated with a reduced-intensity, pre-
parative regimen and underwent family donor alloge-
neic HSCT. The objective of this report was to evaluate
the feasibility of this approach in terms of toxicity and
engraftment and to assess the evidence of potential
GVT effect.
MATERIALS AND METHODS
Patient Population
Eligible patients were age  65 years and had histo-
logically confirmed metastatic tumors that were doc-
umented radiographically as progressive despite prior
therapy and that were not amenable to complete sur-
gical resection or further systemic, conventional treat-
ments. Patients were required to have an HLA-identi-
cal sibling and were excluded if they had bone
metastases alone, if they had active brain metastases,
or if they had received any treatment for their disease
within 30 days before enrollment.
Seventeen consecutive patients underwent non-
myeloablative allogeneic HSCT for progressive dis-
ease. Seven patients had RCC, three patients had
sarcoma (one patient had Ewing sarcoma, one pa-
tient had gastric sarcoma, and one patient had rhab-
domyosarcoma), two patients had breast carcinoma
(BC), two patients had Hodgkin disease (HD), and
one patient each had ovarian carcinoma, mela-
noma, and both melanoma and RCC. The median
age was 43 years (range, 10 – 64). Seven of 17 pa-
tients were female. All patients received transplan-
tation from a molecularly typed, HLA-identical sib-
ling. Seven patients had been treated previously
with at least two lines of chemotherapy (CT), includ-
ing HDC and autologous HSCT. Either immunother-
apy alone or 1 line of CT with or without immuno-
therapy was recorded in the remaining 10 patients.
All patients had multiple sites of metastatic tumor.
The Eastern Cooperative Oncology Group perfor-
mance status (PS) was 0 –1 in 11 patients and 2–3 in
6 patients. Further details on patient characteristics
are reported in Table 1.
HLA-identical sibling donors received 10 g/kg of
recombinant human granulocyte colony-stimulating
factor (G-CSF; Filgrastim) subcutaneously daily for
4 – 6 days. Mobilized peripheral blood stem cells were
collected by leukapheresis on Day 4 and on Days 5 and
6, if needed, to obtain a target dose of  4  106
CD34 cells per kilogram of recipient body weight (Kg
bw). In three patients, the target dose was not reached
despite three consecutive leukaphereses. No positive
selections or T-cell depletion procedures were per-
formed. Patients or their legal guardians as well as
donors gave written, informed consent to participate
into this protocol, which was approved by the Internal
Review Boards of the participating institutions.
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Preparative Regimen: HSCT and Post-Transplantation
Immunosuppression
In selecting a low-intensity, preparative regimen, we
chose two agents with proven immunosuppressive
but nonmyeloablative effects.10,12 The conditioning
regimen consisted of intravenous cyclophosphamide
(CY) 30 mg/Kg bw per day on Day5 and Day4 and
fludarabine (FLU) 30 mg/m2 per day from Day 5 to
Day 2 before patients underwent HSCT. Cyclo-
sporin-A (Cs-A), which was used to prevent both graft
rejection and GVHD, was started 7 days before HSCT
as an intravenous infusion at a dose of 3 mg/Kg per
day. Subsequently, patients received oral Cs-A 6
mg/Kg per day in 2 divided doses. Methotrexate was
administrated as part of GVHD prophylaxis at a dos-
age of 15 mg/m2 intravenously on Day 1 and 10
mg/m2 intravenously on Days 3, 6, and 11 after the
allograft. Post-transplantation, Cs-A was decreased by
20% every week starting from Day 60 and was dis-
continued if severe GVHD had not developed.
Supportive Care
Antimicrobial therapy followed institutional protocols
and consisted of itraconazole for antifungal prophy-
laxis, acyclovir for antiviral prophylaxis, and cipro-
floxacin for antibacterial prophylaxis. Human cyto-
megalovirus (HCMV) serologic status was studied
before transplantation in all patients and their donors.
The expression of pp65 HCMV matrix protein was
monitored to detect HCMV reactivation.17 Patients
who experienced reactivation of HCMV infection were
treated with ganciclovir 10 mg/Kg per day until two
negative controls were produced. For Pneumocystis
carinii pneumonia prophylaxis, patients received oral
cotrimoxazole starting from the day of engraftment.
Empiric, broad-spectrum antibiotic therapy was
started when patients became febrile, and antifungal
therapy was employed in the presence of clinical evi-
dence of fungal infection or fever persisting after 3
days of antibiotic therapy. G-CSF (Filgrastim; 5 g/Kg
per day subcutaneously) was administered if the white
blood cell count fell to 1 109/L after HSCT. Platelet
transfusions were given on a prophylactic basis when
the platelet count was  10  109/L or in the presence
of bleeding episodes, whereas red blood cell units
were transfused in patients with hemoglobin levels
 8 g/dL. All blood products were filtered and irradi-
ated before transfusion.
Assessment of Chimerism, GVHD, and Tumor Response
to Treatment
Myeloid and platelet engraftments were defined as the
first of 3 consecutive days with an absolute neutrophil
count (ANC)  0.5  109/L and unsupported platelets
 50  109/L, respectively. Patients were considered
assessable for engraftment if they survived for at least
14 days after undergoing transplantation. After trans-
plantation, samples of blood were obtained monthly,
and the degree of donor-recipient chimerism in both
myeloid and T-cell lineages was assessed by polymer-
ase chain reaction assay of minisatellite regions, as
reported previously.18
Acute and chronic GVHD were classified accord-
ing to previously described criteria.19,20 Patients with
sustained donor engraftment who survived for  14
days and  100 days after undergoing transplantation
were evaluated for occurrence and severity of acute
and chronic GVHD, respectively. Evaluation of treat-
ment response was performed every month after
transplantation according to the World Health Orga-
nization criteria.
RESULTS
HSCT and Engraftment
Patients received a median of 6.06  106 CD34 he-
matopoietic cells/Kg (range, 1.5–14.0  106 CD34
hematopoietic cells/Kg) and 2.96  108 CD3 T
cells/Kg (range, 0.5–5.7  108 CD3 T cells/Kg). Com-
plete neutrophil and platelet recovery was achieved at
a median of 12 days (range, 5–19 days) and 15 days
(range 11–30 days) after transplantation, respectively.
In 4 patients, the ANC and platelet counts never fell
below 1  109/L and 50  109/L, respectively.
At Day 90, full donor T-cell chimerism was doc-
umented in all patients who were treated previously
with intensive chemotherapy. Stable mixed chimerism
( 50% of donor cells) was observed in four patients
who previously had received only one line of chemo-
therapy and/or cytokine-based therapy.
HSCT-Related Adverse Events
All patients with a PS of 2–3 experienced Grade 4
hematologic toxicity and Grade 3 and 4 organ toxici-
ties in the post-transplantation phase. Among patients
with a PS of 0 –1, 10 patients presented with neutro-
penia and thrombocytopenia of short duration (never
reaching Grade 4) and had no organ toxicity, and 1
patient died of graft failure on Day 29.
Grade 2–3, acute GVHD occurred in five patients
after Cs-A withdrawal (see Table 1). In all patients,
GVHD responded to steroids: Four patients experi-
enced chronic GVHD involving the skin (four patients)
and the gastrointestinal tract (two patients). HCMV
reactivation occurred only in four patients, all of
whom responded promptly to ganciclovir therapy.
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Patient Outcome
Table 1 shows that there were 13 patient deaths. Nine
patients died in the early post-transplantation phase
(i.e., within 100 days from transplantation) due to
transplantation-related complications (n  3 patients;
17%) or progressive disease (n  6 patients; 35%), and
four additional patients died of tumor progression a
median of 254 days post-transplantation (range, 110 –
390 days). Overall, seven patients had evidence of
rapidly progressing tumor after undergoing HSCT, all
of whom had large tumor loads at baseline and died
without signs of tumor regression. Two patients with
BC had early regression of metastases, possibly due to
response to the conditioning regimen, but progressed
thereafter. One patient with Ewing sarcoma had initial
radiographic evidence of tumor growth and subse-
quently had 5 months of stabilization after Cs-A with-
drawal and the development of GVHD. Eventually, he
died of progressive disease on Day 390. One patient
with gastric sarcoma in progression at the time of
HSCT had stable disease for 6 months post-transplan-
tation and subsequently had low progressing disease;
he was alive at Day 280. One patient with rhabdo-
myosarcoma achieved complete remission (Fig. 1)
that lasted for 5 months, but he subsequently experi-
enced disease recurrence and died on Day 231. The
two patients with HD were in complete response and
partial response at Day 208 and Day 240 after
HSCT, respectively. The outcome of patients who had
a follow-up  100 day is reported in detail in Figure 2.
DISCUSSION
Because allogeneic donor lymphocytes have been
reported induce a GVT reaction in patients with leu-
kemia and selected solid tumors, mostly metastatic
RCC,1– 6,16,13,21 we evaluated the feasibility of alloge-
FIGURE 1. Computed tomography
(CT) scan from a patient with rhabdo-
myosarcoma before (A,C) and 3 months
after (B,D) the patient underwent alloge-
neic hematopoietic stem cell transplan-
tation. CT scan sections are not fully
superimposable; however, the overall in-
terpretation of the images shows the
regression of mediastinal tumor masses.
FIGURE 2. Tumor course and out-
come of patients who had a follow-up
 100 days. Patients are listed accord-
ing to their underlying disease (for de-
tails, see text and Table 1). Crosses
indicate patient deaths. HD: Hodgkin
disease; sa.: sarcoma; MM & RCC: ma-
lignant melanoma and renal cell carci-
noma; ca.: carcinoma; CR: complete re-
sponse: PR: partial response: SD: stable
disease: P: progression; GvHD: graft-
versus-host disease  Grade 2.
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neic HSCT after a reduced-intensity, preparative ther-
apy regimen in patients with Stage IV malignancies
that were refractory to conventional management.
Seventeen patients received a reduced-intensity,
highly immunosuppressive, preparative regimen con-
sisting of CY and FLU, followed by the transplantation
of Filgrastin-mobilized blood hematopoietic stem
cells from an HLA-identical sibling. Cs-A and short-
term methotrexate were used to favor engraftment
and to prevent GVHD. The objective of our experi-
mental protocol was to determine whether this regi-
men had acceptable toxicity while establishing a com-
petent donor immune system capable of exerting a
GVT effect.
The data presented in this article indicate that
allogeneic HSCT after a reduced-intensity, CY-FLU
preparative regimen is a feasible procedure for the
treatment of patients with advanced-stage malignan-
cies. The incidence and severity of acute GVHD was
limited, probably due to the effective prophylaxis that
was used. HCMV reactivation, which responded
promptly to antiviral treatment, occurred in only four
patients (24% of the overall population), compared
with a significantly greater proportion of patients who
were given conventional myeloablative therapy in an-
other study.17 With only one exception, none of the
medically fit patients experienced relevant extrahema-
tologic toxicity or life-threatening neutropenia/throm-
bocytopenia. However, major transplantation-related
toxicity and rapidly progressive disease were recorded
in patients with a poor initial presentation (PS, 2–3),
often related to the presence of large tumor masses. In
such patients, severe post-transplantation immuno-
deficiency has the potential to inhibit any immune
antitumor mechanisms, thus promoting disease pro-
gression. This may explain the extremely poor out-
come of our patients with RCC and indicates that
patients with a poor PS and/or rapidly progressing,
metastatic disease are not likely to live long enough for
the generation of a GVT effect and should not be
treated with allogeneic HSCT.
To succeed, immunotherapy with allogeneic lym-
phocytes seems to require the full engraftment of the
donor lymphocytes.12 In the current series, this goal
was obtained only in heavily pretreated patients,
whereas patients who previously had received mild
myelotoxic therapy and/or cytokine-based therapy
(typically patients with melanoma and RCC) achieved
mixed T-cell chimerism. Higher doses of CY or, alter-
natively, post-transplantation donor lymphocyte infu-
sions may aid in achieving full chimerism in a larger
proportion of patients.16 The optimal nonmyeloabla-
tive preparative regimen for patients with solid tu-
mors, as well as for patients with hematologic malig-
nancies, undergoing allograft depends on several
factors, including the aggressiveness of the patient’s
malignancy and the immunocompetence of the recip-
ient. We combined CY with the potent immunosup-
pressive purine analogue FLU, which has been a com-
ponent of most other reported reduced-intensity,
preparative, allografting regimens. Previous studies
have shown that FLU-based preparative regimens are
well tolerated and are used currently in patients who
are not eligible for conventional myeloablative condi-
tioning because of advanced age and/or poor
PS.8,9,13,16,21 Immune-compromised patients, such pa-
tients who were treated previously with intensified
chemoradiotherapy, may require less intensive immu-
nosuppression to achieve engraftment than a fully
immunocompetent recipient.10,13,16 By contrast, in pa-
tients with highly proliferative malignancies, a more
aggressive conditioning regimen, along with a rapid
tapering of post-transplantation immunosuppression
therapy, may favor the generation of a GVT effect
more rapidly. In our experience, some patients have
shown a response or disease stabilization after al-
lografting, confirming that a GVT effect can be gener-
ated in solid tumors other than RCC. In particular,
patients with sarcoma have shown some promising
results. However, due to the limited number of pa-
tients enrolled in our study, data on the clinical out-
come should be considered with great caution.
The results published to date in animal mod-
els14,15 and, more recently, in human patients,4 – 6,16
including our own experience, provide evidence of the
therapeutic usefulness of the allogeneic GVT effect
also in patients with nonhematologic malignancies.
Therefore, it is likely that increasing numbers of in-
vestigators will perform allogeneic HSCT in patients
with a widening variety of solid tumors. Because solid
tumors show a wide diversity of etiology and antigen
characteristics, it will be necessary to evaluate this
approach in patients with each disease individually. In
this regard, it is mandatory to treat patients in insti-
tutions that have proven experience in this setting and
in the context of specific clinical trials that are de-
signed to address major clinical and biologic issues in
this field. In particular, great attention should be paid
to developing a better understanding of the mecha-
nisms of immune escape used by tumor cells and how
to restore immune competence against malignant dis-
ease.22
Clinical studies reported to date, along with the
current data, have recognized that proof of the two
principles already is at hand: allogeneic T cells can
induce clinically relevant responses in patients with
RCC and other solid tumors, and donor lymphocytes
can survive in the host after nonmyeloablative condi-
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tioning. In the near future, a clinical improvement in
this setting is likely to depend on the possibility of
driving the donor immune system in a specific fashion
against antigens exclusively or preferentially pre-
sented by tumor cells without damaging normal so-
matic host cells.
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